Compare RBBN & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | ORGO |
|---|---|---|
| Founded | 1997 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.6M | 348.6M |
| IPO Year | 2017 | 2016 |
| Metric | RBBN | ORGO |
|---|---|---|
| Price | $2.18 | $2.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.67 | ★ $8.50 |
| AVG Volume (30 Days) | 536.9K | ★ 545.0K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 170.97 | ★ 1600.00 |
| EPS | ★ 0.22 | 0.15 |
| Revenue | N/A | ★ $564,169,000.00 |
| Revenue This Year | $1.97 | N/A |
| Revenue Next Year | $6.69 | $26.27 |
| P/E Ratio | ★ $9.91 | $14.93 |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $1.83 | $2.21 |
| 52 Week High | $4.29 | $7.08 |
| Indicator | RBBN | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 24.54 |
| Support Level | $2.07 | N/A |
| Resistance Level | $2.27 | $2.51 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 60.87 | 5.98 |
Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.